Many weight management solutions available today ultimately fail – partly because patients do not receive the help they need, when they need it.... Jun 20
Pharma merger and acquisitions... Jul 15
Colorcon will collaborate with i2O to accelerate i2O’s research and development efforts... Dec 04
Teplizumab, Provention Bio’s lead drug candidate, is an anti-CD3 monoclonal antibody (mAb) being developed for the delay or prevention of type 1 diabetes ... Aug 29
Children diagnosed with type 1 diabetes under the age of seven have a different form of the condition than those aged 13 or over, research ... Mar 18
-Advertisements-